-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, the domestic innovative drug industry has been developing in full swing.
In the context of fierce market competition, more and more companies have begun to go global
.
It is understood that since Microchip Technology authorized Cedarbenamide to US HUYA at a price of tens of millions of dollars in 2007, innovative pharmaceutical companies have continued to emerge, and since 2021, the trend has been even worse
.
According to incomplete statistics in the industry, since 2021, the number of overseas authorized transactions by local pharmaceutical companies has exceeded 30, involving pharmaceutical companies such as BeiGene, Rongchang Biotechnology, and Livzon Group
.
Judging from the amount of a single transaction this year, the transaction amount reached a new high during the year
.
Among them, Rongchang Biologics has the highest amount.
On August 8, 2021, Rongchang Biologics reached a cooperation agreement with Seattle Genes to develop and commercialize its new ADC drug, vedicitumumab.
The transaction amount was as high as US$2.
6 billion.
At the same time, Rongchang Bio will receive a gradient sales commission from the high single-digit to more than ten percent of the net sales of Vidicuzumab in the Seattle gene region
.
The amount of this transaction set a record for the overseas authorized transactions of a single-variety local innovative drug company
.
It is understood that vedicitumumab is a new ADC drug targeting HER2.
It has shown clinical anti-tumor activity in HER2-expressing urothelial cancer, gastric cancer, breast cancer and other tumors.
In addition, the drug is compatible with The combined therapeutic effect of PD-1 drugs has also been confirmed in clinical trials of urothelial cancer
.
At present, vedicitumumab has been approved by the US FDA and the China Food and Drug Administration for breakthrough therapy for the treatment of urothelial cancer, and it has been approved by the China Food and Drug Administration for the treatment of advanced breast cancer
.
The drug has received conditional marketing approval in China for the treatment of locally advanced metastatic gastric cancer
.
On July 14, the China Food and Drug Administration accepted its new drug application for the treatment of locally advanced or metastatic urothelial cancer
.
In addition, BeiGene is also very active
.
In January of this year, BeiGene and Novartis reached a cooperation agreement to authorize Novartis to develop, manufacture and commercialize tislelizumab in North America, Europe and Japan.
The transaction amounted to US$2.
2 billion.
.
Tilelizumab is an innovative PD-1 antibody independently developed by BeiGene.
It is used to treat the failure of platinum-containing chemotherapy with high expression of PD-L1, including neoadjuvant or adjuvant chemotherapy, which has progressed locally late or metastasis within 12 months Sexual urothelial carcinoma
.
At present, the product has been approved for five indications in China, and 35 clinical trials are carried out globally, covering various cancer types such as non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and gastric cancer
.
In addition to the authorization of tislelizumab to Novartis, BeiGene also announced on November 24 that the European Commission had approved Baiyueze for the treatment of adults with Waldenstrom's macroglobulinemia (WM) who had received at least one treatment in the past.
Patients, or as a first-line treatment option for WM patients who are not suitable for chemotherapy and immunotherapy, the approval applies to all 27 member states of the European Union, as well as Iceland and Norway
.
At present, the drug has been approved for marketing in the United States, China, the European Union and 9 other countries and regions
.
It is reported that, in order to speed up the process of going to sea, on November 23, BeiGene also announced that it has completed the acquisition of land for the Princeton West Innovation Park in Hopewell, New Jersey, USA, for the construction of 42 acres (about 170,000 square meters).
) Innovative drug production base
.
After the completion of the base, it will further expand and enrich the company's global supply chain, and build new production capacity for the company's deep biopharmaceutical product pipeline and drug candidates
.
In addition to the above-mentioned drugs, projects with higher domestic license-out transactions this year also include lemzoparlimab, abutinib, and vomitinib
.
From the perspective of the industry, with the rise of domestic innovative pharmaceutical companies, more and more independent research and development companies will be recognized by international companies.
Under the pressure of domestic price cuts, the return space of innovative drugs after the listing is constantly being squeezed, and the future is expected Local pharmaceutical companies' "going out of the sea" will become a trend, and industry competition will further intensify
.
In the context of fierce market competition, more and more companies have begun to go global
.
It is understood that since Microchip Technology authorized Cedarbenamide to US HUYA at a price of tens of millions of dollars in 2007, innovative pharmaceutical companies have continued to emerge, and since 2021, the trend has been even worse
.
According to incomplete statistics in the industry, since 2021, the number of overseas authorized transactions by local pharmaceutical companies has exceeded 30, involving pharmaceutical companies such as BeiGene, Rongchang Biotechnology, and Livzon Group
.
Judging from the amount of a single transaction this year, the transaction amount reached a new high during the year
.
Among them, Rongchang Biologics has the highest amount.
On August 8, 2021, Rongchang Biologics reached a cooperation agreement with Seattle Genes to develop and commercialize its new ADC drug, vedicitumumab.
The transaction amount was as high as US$2.
6 billion.
At the same time, Rongchang Bio will receive a gradient sales commission from the high single-digit to more than ten percent of the net sales of Vidicuzumab in the Seattle gene region
.
The amount of this transaction set a record for the overseas authorized transactions of a single-variety local innovative drug company
.
It is understood that vedicitumumab is a new ADC drug targeting HER2.
It has shown clinical anti-tumor activity in HER2-expressing urothelial cancer, gastric cancer, breast cancer and other tumors.
In addition, the drug is compatible with The combined therapeutic effect of PD-1 drugs has also been confirmed in clinical trials of urothelial cancer
.
At present, vedicitumumab has been approved by the US FDA and the China Food and Drug Administration for breakthrough therapy for the treatment of urothelial cancer, and it has been approved by the China Food and Drug Administration for the treatment of advanced breast cancer
.
The drug has received conditional marketing approval in China for the treatment of locally advanced metastatic gastric cancer
.
On July 14, the China Food and Drug Administration accepted its new drug application for the treatment of locally advanced or metastatic urothelial cancer
.
In addition, BeiGene is also very active
.
In January of this year, BeiGene and Novartis reached a cooperation agreement to authorize Novartis to develop, manufacture and commercialize tislelizumab in North America, Europe and Japan.
The transaction amounted to US$2.
2 billion.
.
Tilelizumab is an innovative PD-1 antibody independently developed by BeiGene.
It is used to treat the failure of platinum-containing chemotherapy with high expression of PD-L1, including neoadjuvant or adjuvant chemotherapy, which has progressed locally late or metastasis within 12 months Sexual urothelial carcinoma
.
At present, the product has been approved for five indications in China, and 35 clinical trials are carried out globally, covering various cancer types such as non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and gastric cancer
.
In addition to the authorization of tislelizumab to Novartis, BeiGene also announced on November 24 that the European Commission had approved Baiyueze for the treatment of adults with Waldenstrom's macroglobulinemia (WM) who had received at least one treatment in the past.
Patients, or as a first-line treatment option for WM patients who are not suitable for chemotherapy and immunotherapy, the approval applies to all 27 member states of the European Union, as well as Iceland and Norway
.
At present, the drug has been approved for marketing in the United States, China, the European Union and 9 other countries and regions
.
It is reported that, in order to speed up the process of going to sea, on November 23, BeiGene also announced that it has completed the acquisition of land for the Princeton West Innovation Park in Hopewell, New Jersey, USA, for the construction of 42 acres (about 170,000 square meters).
) Innovative drug production base
.
After the completion of the base, it will further expand and enrich the company's global supply chain, and build new production capacity for the company's deep biopharmaceutical product pipeline and drug candidates
.
In addition to the above-mentioned drugs, projects with higher domestic license-out transactions this year also include lemzoparlimab, abutinib, and vomitinib
.
From the perspective of the industry, with the rise of domestic innovative pharmaceutical companies, more and more independent research and development companies will be recognized by international companies.
Under the pressure of domestic price cuts, the return space of innovative drugs after the listing is constantly being squeezed, and the future is expected Local pharmaceutical companies' "going out of the sea" will become a trend, and industry competition will further intensify
.
